Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

Status:

NO_LONGER_AVAILABLE

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

Lead Sponsor:

Mesoblast International Sàrl

Conditions:

Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19

Eligibility:

All Genders

18+ years

Brief Summary

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).

Detailed Description

This intermediate-size expanded access protocol plans to treat approximately 50 adult participants, male and female, with moderate to severe ARDS due to COVID-19 infection. Participants who are 18 yea...

Eligibility Criteria

Inclusion

18 years or older
Participant has coronavirus disease COVID-19 confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay or another diagnostic test
Moderate to severe ARDS as determined by the following criteria (adapted from the Berlin criteria):
Bilateral opacities must be present on a chest radiograph or computed tomographic (CT) scan. These opacities are not fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules.
Respiratory failure not fully explained by cardiac failure or fluid overload. An objective assessment (e.g., echocardiography) to exclude hydrostatic pulmonary edema is required if no risk factors for ARDS are present.
Moderate to severe impairment of oxygenation must be present, as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2). The severity of the hypoxemia defines the severity of the ARDS:
Moderate ARDS: e PaO2/FiO2 \>100 millimeters of mercury (mmHg) and ≤200 mmHg, on ventilator settings that include positive end-expiratory pressure (PEEP) ≥5 centimeters (cm) of water OR
Severe ARDS: PaO2/FiO2 ≤100 mmHg on ventilator settings that include PEEP ≥5 cm of water
≤72 hours post-initiation of ventilation
High sensitivity C-reactive protein (hs-CRP) serum level ≥ 4.0 milligrams per deciliter (mg/dL)
Acute Physiologic and Chronic Health Evaluation (APACHE II) score ≥5
Aspartate aminotransferase/alanine transaminase (AST/ALT) \< 5x upper limit of normal (ULN)
Creatinine clearance ≥ 30 milliliters per minute (mL/min)
Serum creatinine \<2 mg/dL

Exclusion

Participant is receiving extracorporeal membrane oxygenation (ECMO)
Females who are pregnant or lactating
Known hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins
Severe chronic obstructive pulmonary disease (COPD) requiring oxygen therapy prior to becoming ill with ARDS due to COVID-19 infection
Any end-stage organ disease which, in the opinion of the treating physician, may possibly affect the safety of the remestemcel-L treatment

Key Trial Info

Start Date :

Trial Type :

EXPANDED_ACCESS

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04366830

Last Update

February 18 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)